Suppr超能文献

新辅助治疗后获得完全或接近完全临床缓解的直肠癌患者的长期结局:一项来自中国观察与等待数据库的多中心注册研究数据

[Long-term outcome of patients with rectal cancer who achieve complete or near complete clinical responses after neoadjuvant therapy: a multicenter registry study of data from the Chinese Watch and Wait Database].

作者信息

Zhao Y M, Wang W H, Zhang W, Wang L, Li S, Wang J W, Liao L E, Yu G Y, Sun Z, Qu Y L, Gong Y, Lu Y, Wu T, Li Y F, Wang Q, Zhao G H, Xiao Y, Ding P R, Zhang Z, Wu A W

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing),Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital & Institute, Beijing 100142,China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

出版信息

Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Apr 25;27(4):372-382. doi: 10.3760/cma.j.cn441530-20240227-00074.

Abstract

To report the long-term outcomes of Chinese rectal cancer patients after adopting a Watch and Wait (W&W) strategy following neoadjuvant therapy (NAT). This multicenter, cross-sectional study was based on real-world data. The study cohort comprised rectal cancer patients who had achieved complete or near complete clinical responses (cCRs, near-cCRs) after NAT and were thereafter managed by a W&W approach, as well as a few patients who had achieved good responses after NAT and had then undergone local excision for confirmation of pathological complete response. All participants had been followed up for ≥2 years. Patients with distant metastases at baseline or who opted for observation while living with the tumor were excluded. Data of eligible patients were retrospectively collected from the Chinese Wait-and-Watch Data Collaboration Group database. These included baseline characteristics, type of NAT, pre-treatment imaging results, evaluation of post-NAT efficacy, salvage measures, and treatment outcomes. We herein report the long-term outcomes of Chinese rectal cancer patients after NAT and W&W and the differences between the cCR and near-cCR groups. Clinical data of 318 rectal cancer patients who had undergone W&W for over 2 years and been followed up were collected from eight medical centers (Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center, Shanghai Changhai Hospital, Peking Union Medical College Hospital, Liaoning Cancer Hospital, the First Hospital of Jilin University, and Yunnan Cancer Hospital.) The participants comprised 221 men (69.4%) and 107 women (30.6%) of median age 60 (26-86) years. The median distance between tumor and anal verge was 3.4 (0-10.4) cm. Of these patients, 291 and 27 had achieved cCR or near-cCR, respectively, after NAT. The median duration of follow-up was 48.4 (10.2-110.3) months. The 5-year cumulative overall survival rate was 92.4% (95%CI: 86.8%-95.7%), 5-year cumulative disease-specific survival (CSS) rate 96.6% (95%CI: 92.2%-98.5%), 5-year cumulative organ-preserving disease-free survival rate 86.6% (95%CI: 81.0%-90.7%), and 5-year organ preservation rate 85.3% (95%CI: 80.3%-89.1%). The overall 5-year local recurrence and distant metastasis rates were 18.5% (95%CI: 14.9%-20.8%) and 8.2% (95%CI: 5.4%-12.5%), respectively. Most local recurrences (82.1%, 46/56) occurred within 2 years, and 91.0% (51/56) occurred within 3 years, the median time to recurrence being 11.7 (2.5-66.6) months. Most (91.1%, 51/56) local recurrences occurred within the intestinal lumen. Distant metastases developed in 23 patients; 60.9% (14/23) occurred within 2 years and 73.9% (17/23) within 3 years, the median time to distant metastasis being 21.9 (2.6-90.3) months. Common sites included lung (15/23, 65.2%), liver (6/23, 26.1%), and bone (7/23, 30.4%) The metastases involved single organs in 17 patients and multiple organs in six. There were no significant differences in overall, cumulative disease-specific, or organ-preserving disease-free survival or rate of metastases between the two groups (all >0.05). The 5-year local recurrence rate was higher in the near-cCR than in the cCR group (41.6% vs. 16.4%, <0.01), with a lower organ preservation rate (69.2% vs. 88.0%, <0.001). The success rates of salvage after local recurrence and distant metastasis were 82.1% (46/56) and 13.0% (3/23), respectively. Rectal cancer patients who achieve cCR or near-cCR after NAT and undergo W&W have favorable oncological outcomes and a high rate of organ preservation. Local recurrence and distant metastasis during W&W follow certain patterns, with a relatively high salvage rate for local recurrence. Our findings highlight the importance of close follow-up and timely intervention during the W&W process.

摘要

报告中国直肠癌患者在新辅助治疗(NAT)后采用观察等待(W&W)策略的长期结局。这项多中心横断面研究基于真实世界数据。研究队列包括在NAT后达到完全或接近完全临床缓解(cCR、接近cCR)并随后采用W&W方法管理的直肠癌患者,以及少数在NAT后取得良好反应并随后接受局部切除以确认病理完全缓解的患者。所有参与者均随访≥2年。排除基线时有远处转移或选择带瘤观察的患者。符合条件患者的数据从中国观察等待数据协作组数据库中回顾性收集。这些数据包括基线特征、NAT类型、治疗前影像学结果、NAT后疗效评估、挽救措施和治疗结局。我们在此报告中国直肠癌患者在NAT和W&W后的长期结局以及cCR组和接近cCR组之间的差异。从八个医学中心(北京大学肿瘤医院、复旦大学附属肿瘤医院、中山大学肿瘤防治中心、上海长海医院、北京协和医院、辽宁省肿瘤医院、吉林大学第一医院和云南省肿瘤医院)收集了318例接受W&W超过2年并进行随访的直肠癌患者的临床数据。参与者包括221名男性(69.4%)和107名女性(30.6%),中位年龄60(26 - 86)岁。肿瘤距肛缘的中位距离为3.4(0 - 10.4)cm。在这些患者中,291例和27例在NAT后分别达到cCR或接近cCR。中位随访时间为48.4(10.2 - 110.3)个月。5年累积总生存率为92.4%(95%CI:86.8% - 95.7%),5年累积疾病特异性生存率(CSS)为96.6%(95%CI:92.2% - 98.5%),5年累积保器官无病生存率为86.6%(95%CI:81.0% - 90.7%),5年器官保留率为85.3%(95%CI:80.3% - 89.1%)。5年总体局部复发率和远处转移率分别为18.5%(95%CI:14.9% - 20.8%)和8.2%(95%CI: 5.4% - 12.5%)。大多数局部复发(82.1%,46/56)发生在2年内,91.0%(51/56)发生在3年内,复发的中位时间为11.7(2.5 - 66.6)个月。大多数(91.1%,51/56)局部复发发生在肠腔内。23例患者发生远处转移;60.9%(14/23)发生在2年内,73.9%(17/23)发生在3年内,远处转移的中位时间为21.9(2.6 - 90.3)个月。常见部位包括肺(15/23,65.2%)、肝(6/23,26.1%)和骨(7/23,30.4%)。17例患者转移累及单个器官,6例累及多个器官。两组在总体、累积疾病特异性或保器官无病生存率或转移率方面无显著差异(均>0.05)。接近cCR组的5年局部复发率高于cCR组(41.6%对16.4%,<0.01),器官保留率较低(69.2%对88.0%,<0.001)。局部复发和远处转移后的挽救成功率分别为82.1%(46/56)和13.0%(3/23)。在NAT后达到cCR或接近cCR并接受W&W的直肠癌患者具有良好的肿瘤学结局和较高的器官保留率。W&W期间局部复发和远处转移遵循一定模式,局部复发的挽救率相对较高。我们的研究结果强调了W&W过程中密切随访和及时干预的重要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验